FDA approvals extend Enhertu into curative-intent HER2-positive early breast cancer

An update from AstraZeneca ( (GB:AZN) ) is now available.

AstraZeneca and Daiichi Sankyo have secured U.S. FDA approval for two new indications of Enhertu in HER2-positive early breast cancer, covering both neoadjuvant and adjuvant use based on Phase III DESTINY-Breast11 and DESTINY-Breast05 trials. The drug, already a mainstay in metastatic disease, is now positioned as a foundational therapy in early-stage HER2-positive breast cancer, moving into the curative-intent setting and reinforcing its role across the disease continuum.

DESTINY-Breast11 showed Enhertu followed by a taxane, trastuzumab and pertuzumab delivered higher pathologic complete response rates than standard ddAC-THP regimens, while DESTINY-Breast05 demonstrated a 53% reduction in invasive disease recurrence or death versus T-DM1 in patients with residual disease after neoadjuvant therapy. The approvals trigger $155 million in milestone payments from AstraZeneca to Daiichi Sankyo, support Enhertu’s inclusion as a Category 1 adjuvant option in NCCN guidelines, and further entrench the partners’ antibody drug conjugate franchise in a large, high-risk patient population, despite known interstitial lung disease risks that regulators and clinicians will monitor closely.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

The score is driven primarily by strong underlying fundamentals (profitability, margins, and returns) and a constructive earnings update with reiterated guidance and meaningful pipeline progress. These positives are partly offset by weak technical momentum, moderate valuation, and near-term cash/debt pressures tied to higher investment and payments.

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global biopharmaceutical company focused on discovering, developing and commercialising prescription medicines, particularly in oncology, cardiovascular, renal and metabolic diseases, and respiratory conditions. In oncology, it is expanding its portfolio of targeted therapies and antibody drug conjugates to strengthen its position in key cancer indications such as breast cancer.

Average Trading Volume: 2,604,419

Technical Sentiment Signal: Buy

Current Market Cap: £211.4B

See more insights into AZN stock on TipRanks’ Stock Analysis page.